Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Journal Information
Full Title: EBioMedicine
Abbreviation: EBioMedicine
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Genetics, Medical
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declaration of interests Liangzhi Xie, Wenlin Gai, and Yan Wang are employees of Sinocelltech Ltd., Beijing, China. Peng Meng is employee of Burning Rock Biotech, Shanghai, China. The other authors declare that there is no conflict of interests regarding the publication of this article."
"The study protocols were approved by the ethics committee of all the participating hospitals in accordance with the Declaration of Helsinki and its amendments. Written informed consent of every patient was obtained before enrollment. The clinical trial registration number was NCT03405272."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025